- Under a restructuring plan, Japan-based pharma Eisai will axe 25% of its U.S. workforce.
- The company's stated goal is to become more efficient, remain competitive, and redeploy resources towards development of late-stage candidates.
- The new structure is expected to be in place by May 1.
Like other biopharma companies, Eisai is trying to focus on its strengths while cost-cutting in order to become more efficient. The layoffs will be across the board and will affect all U.S.-based functions, including R&D, manufacturing, sales and marketing, and administrative functions. Much of the cost-savings will be directed towards its late-stage candidates in its core areas of focus, including neurology, oncology and metabolic diseases.
On the bright side, Eisai does not plan to close any of its main offices or facilities, including its U.S. headquarters in Woodcliffe, NJ.